Pharmacokinetics, pharmacodynamics and safety of the novel C-X-C chemokine receptor 3 antagonist ACT-777991: Results from the first-in-human study in healthy adults.

Autor: Boof ML; Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland., Géhin M; Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland., Voors-Pette C; QPS Netherlands BV, Groningen, The Netherlands., Hsin CH; Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland., Sippel V; Department of Translational Biomarkers, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland., Strasser DS; Department of Translational Biomarkers, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland., Dingemanse J; Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.

Publikováno v: British journal of clinical pharmacology [Br J Clin Pharmacol] 2024 Feb; Vol. 90 (2), pp. 588-599. Date of Electronic Publication: 2023 Nov 16.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Effect of Renal Function Impairment on the Pharmacokinetics, Safety, and Tolerability of the Iminosugar Sinbaglustat.

Autor: Melchior M; Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland., Dingemanse J; Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland., Alatrach A; Clinical Research Services Kiel GmbH, Kiel, Germany., Feldkamp T; Department of Nephrology and Hypertension, University Hospital Schleswig-Holstein, Christian Albrechts University Kiel, Kiel, Germany., Sidharta PN; Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland., Géhin M; Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.

Publikováno v: Journal of clinical pharmacology [J Clin Pharmacol] 2021 Jul; Vol. 61 (7), pp. 932-938. Date of Electronic Publication: 2021 Jan 15.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Pharmacokinetics, pharmacodynamics, tolerability and prediction of clinically effective dose of ACT-774312: A novel CRTH2 antagonist.

Autor: Géhin M; Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland., Lott D; Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland., Farine H; Department of Translational Science Biology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland., Issac M; Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland., Strasser D; Department of Translational Science Biology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland., Sidharta P; Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland., Dingemanse J; Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.

Publikováno v: Basic & clinical pharmacology & toxicology [Basic Clin Pharmacol Toxicol] 2019 Jun; Vol. 124 (6), pp. 711-721. Date of Electronic Publication: 2019 Feb 11.